Ramirez, Lorenzo Antonio

Email Address
ORCID
Disciplines
Research Projects
Organizational Units
Position
Introduction
Research Interests

Filters

1
20141
1
1
Reset filters

Settings

Search Results

Now showing 1 - 1 of 1
  • Publication
    Enhancing T-Cell Responses to Vaccination of HIV-1 infected Subjects on Antiretroviral Therapy
    (2014-01-01) Ramirez, Lorenzo Antonio
    With the advancement in anti-retroviral therapy (ART) regimens there has been a significant improvement in the quality of life and survival of those individuals infected with HIV-1. Even with the benefits to CD4+ cell counts, decrease in viremia and inflammatory biomarkers, HIV-1 infected individuals continue to exhibit functional issues in their T-cell immune responses to recall antigens and vaccines. Additionally, researchers believe that T-cell mediated responses will be important to elicit in a therapeutic vaccination setting. These T-cell functionality issues can leave individuals infected with HIV-1 at risk from opportunistic infections and co-morbidities. Furthermore, a therapeutic HIV-1 vaccine is needed that can elicit responses to help infected subjects better control HIV infection so as to potentially reduce the need for long-term therapy. However, basic research on HIV is still needed to solidify potential immune correlates against HIV and other pathogens affecting HIV-1 infected subjects. Likewise, investigation of therapeutic targets that can aid in enhancing T-cell immune responses in these individuals is of importance. In this thesis, we examined whether a therapeutic HIV-1 DNA vaccine delivered with in vivo electroporation to HIV-1 infected subjects on ART could elicit potent cellular immune responses previously suggested to be important in the control of HIV. This vaccine strategy demonstrated an enhancement in cell-mediated IFN-γ production and cytotoxic immune responses to HIV-1. However, until a vaccine or therapy for HIV-1 is developed, these individuals also continue to be at risk for other opportunistic infections, such as influenza infection. Supported by previous studies that focus on influenza vaccination, we found that a standard dose of the H1N1 vaccine (15μg; Novartis) did not elicit sero-protection in all individuals. Importantly, the ability of these individuals to respond to vaccination was associated with the frequency of naïve CD4+ T-cells prior to vaccination, thereby reinforcing the importance of CD4+ T-cell help and the need for better CD4+ T-cell reconstitution. In addition, HIV-1 infected subjects, despite ART, have an altered cytokine/chemokine environment. Thereby it is important to explore whether targeting the cytokine milieu can lead to improvements in responses to vaccination in these individuals. We specifically found that the pro-inflammatory chemokine IP-10 was elevated in the sera of those infected with HIV-1 while on ART. Additionally, elevated levels of IP-10 were associated with decreased cellular immune responses, which could be improved by neutralizing IP-10 prior to antigen stimulation. Therefore, the studies herein support the need for better understanding of the basic science of HIV-1 infection to uncover and comprehend what potential immune correlates are needed for therapeutic treatment of these individuals.